A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Status:
Recruiting
Trial end date:
2025-07-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of ustekinumab dosing in inducing
clinical remission (Global) and in maintaining clinical remission (US); to evaluate the
safety profile and ustekinumab exposure (pharmacokinetics [PK]) in pediatric participants
with moderately to severely active Crohn's disease.